NCT02991612

Rifaximin in Patients With Gastroesophageal Variceal Bleeding

Efficacy of Rafiximin in Patients With Cirrhotic Gastroesophageal Variceal Hemorrhage: A Single-center Pilot Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Detailed description

Gastroesophageal variceal bleeding is the most common and life-threatening condition in patients with portal hypertension, which are susceptibility to bacterial infection. However, the prophylaxis use of antibiotics remained uncertain and lack of high level evidences.

Conditions

• Cirrhosis
• Esophageal and Gastric Varices
• Gastrointestinal Hemorrhage

Interventions

Type	Name	Description
DRUG	Rifaximin	Patients receive Rifaximin 400mg bid for 2 months

Timeline

• Start date: 2016-11-25
• Primary completion: 2017-12-22
• Completion: 2018-02-28
• First posted: 2016-12-13
• Last updated: 2018-05-11

Locations

1 site across 1 country: China